Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 9:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 189 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: COMBO Clear all
Recruiting Phase 1Phase 2 Interventional

A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

NCT06706076
View directory record Official record
Conditions
NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions
BH-30643, BH-30643 combo therapy with Carboplatin/Pemetrexed
Drug
Lead sponsor
BlossomHill Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
24
States / cities
Phoenix, Arizona • Irvine, California • La Jolla, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 22, 2026, 9:02 AM EDT
Completed No phase listed Observational

Use of CoG by Patients With Diabetes Mellitus

NCT03840161
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
non-invasive tissue glucose prediction
Device
Lead sponsor
Sciema UG
Other
Eligibility
18 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Mateo, California
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 22, 2026, 9:02 AM EDT
Completed Phase 1 Interventional Results available

ABEMA Alone or in COMBO With MK-6482

NCT04627064
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma
Interventions
Abemaciclib, MK-6482
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 25, 2025 · Synced Oct 22, 2026, 9:02 AM EDT
Completed Not applicable Interventional

The Patterns of Activity and Cognition During Treatment (PACT) Study

NCT04562987
View directory record Official record
Conditions
Breast Neoplasms, Breast Cancer Female
Interventions
Physical Activity, Attentional Control
Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
21 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 22, 2026, 9:02 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of AC-150 for the Treatment of Allergic Conjunctivitis in the Enviro-CAC™ Model

NCT01134328
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
AC-150 Combo, AC-150A 0.1%, AC-150B 0.005%, Vehicle
Drug
Lead sponsor
Aciex Therapeutics, Inc.
Industry
Eligibility
10 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Oct 22, 2026, 9:02 AM EDT
Completed Phase 1 Interventional

Palbociclib in Combo w/Chemotherapy in Peds Relapsed/Refractory Acute Lymphoblastic Leukemia

NCT04996160
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Pediatric, Relapsed Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
Interventions
Palbociclib, Dexamethasone, Bortezomib, Doxorubicin
Drug
Lead sponsor
Tanja Andrea Gruber
Other
Eligibility
Up to 25 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 22, 2026, 9:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Palonosetron and Hydroxyzine to Reduce Opioid Withdrawal

NCT00661674
View directory record Official record
Conditions
Substance-Related Disorders
Interventions
Palonosetron, Hydroxyzine, Placebo
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 22, 2026, 9:02 AM EDT
Recruiting Not applicable Interventional

PRIME HFrEF: Novel Exercise for Older Patients With Heart Failure With Reduced Ejection Fraction

NCT05609097
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction
Interventions
PRIME, COMBO
Other
Lead sponsor
University of Virginia
Other
Eligibility
65 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 6, 2025 · Synced Oct 22, 2026, 9:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Study to Examine Health Behavior Change Strategies for Primary Care

NCT01323023
View directory record Official record
Conditions
Tobacco Use, Risky Drinking, Unhealthy Diet, Physical Inactivity
Interventions
varies by project
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
2 Years and older
Enrollment
4,463 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2013
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 1, 2015 · Synced Oct 22, 2026, 9:02 AM EDT
Completed Phase 2 Interventional

Effects of Resistance and Aerobic Exercise on Cardiovascular Health

NCT00275145
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Obesity, Hyperlipidemia, Insulin Resistance, Metabolic Syndrome X
Interventions
Resistance Training, Aerobic Exercise, Combo, Continued Sedentary lifestyle
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 70 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 24, 2013 · Synced Oct 22, 2026, 9:02 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)

NCT01644175
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Placebo (for alirocumab), Alirocumab, Lipid-Modifying Therapy (LMT)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
76
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 68 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2015 · Synced Oct 22, 2026, 9:02 AM EDT
Terminated Phase 1 Interventional

Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies

NCT04465487
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
REGN6569, Cemiplimab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
4
States / cities
Los Angeles, California • Tampa, Florida • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 22, 2026, 9:02 AM EDT
Terminated Phase 1 Interventional

Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)

NCT02203773
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelogenous Leukemia, Treatment Naive AML
Interventions
Posaconazole, ABT-199, Decitabine, Azacitidine
Drug
Lead sponsor
AbbVie
Industry
Eligibility
60 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
13
States / cities
Duarte, California • Sacramento, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Oct 22, 2026, 9:02 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer

NCT05318573
View directory record Official record
Conditions
Advanced Urothelial Carcinoma, Advanced Non Small Cell Lung Cancer
Interventions
Pembrolizumab, FF-10832
Drug
Lead sponsor
Fujifilm Pharmaceuticals U.S.A., Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
23
States / cities
Long Beach, California • San Diego, California • Washington D.C., District of Columbia + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Oct 22, 2026, 9:02 AM EDT
Recruiting Phase 1 Interventional

Relugolix + Enzalutamide Study in High-Risk Prostate Cancer

NCT06130995
View directory record Official record
Conditions
Androgen Deprivation Therapy, Locally Advanced Prostate Cancer
Interventions
Relugolix and Enzalutamide
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older · Male only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 22, 2026, 9:02 AM EDT
Completed Not applicable Interventional

Impact of Weight Loss on Physical Function

NCT02079051
View directory record Official record
Conditions
Obesity
Interventions
Moderate intensity weight loss, High intensity medical weight loss
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
65 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 22, 2026, 9:02 AM EDT
Terminated Not applicable Interventional

A Trial Comparing Three Orthobiologic Therapies on Atrophied Multifidus Muscles in Patients With Low Back Pain

NCT03618979
View directory record Official record
Conditions
Low Back Pain
Interventions
PPP treatment, PRP treatment, PRP and PL Combo treatment
Biological
Lead sponsor
Regenexx, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Broomfield, Colorado • Lone Tree, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 8, 2022 · Synced Oct 22, 2026, 9:02 AM EDT
Completed No phase listed Observational

Evaluation of COVID-19 and Flu A/B 3 in 1 Combo Rapid Test

NCT07190131
View directory record Official record
Conditions
COVID - 19, Influenza A, Influenza B
Interventions
Investigational Flu A/B And Covid-19 Diagnostic Test
Diagnostic Test
Lead sponsor
iHealth Labs inc
Industry
Eligibility
2 Years and older
Enrollment
588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
14
States / cities
Birmingham, Alabama • Trussville, Alabama • Dublin, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 22, 2026, 9:02 AM EDT
Terminated Phase 1 Interventional Results available

Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)

NCT01400451
View directory record Official record
Conditions
Melanoma
Interventions
Ipilimumab (BMS-734016), Vemurafenib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 1, 2015 · Synced Oct 22, 2026, 9:02 AM EDT
Completed Phase 1 Interventional

Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG

NCT00613132
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
Gleevec, RAD001, and Hydroxyurea
Drug
Lead sponsor
Annick Desjardins
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Oct 22, 2026, 9:02 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Trial of Varenicline With Nicotine Lozenges and a Smartphone Medication Adherence Intervention for Smoking Cessation

NCT07099638
View directory record Official record
Conditions
Smoking Cessation
Interventions
Varenicline (VAR), Nicotine lozenge (NRT), Smartphone intervention with adherence components (COMBO-A), Smartphone intervention without adherence components (COMBO-B), Telephone Counseling
Drug · Behavioral
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
496 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 22, 2026, 9:02 AM EDT
Terminated Phase 2 Interventional Results available

Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC

NCT01995058
View directory record Official record
Conditions
Prostate Cancer, Castration Resistant Prostate Cancer, Prostatic Neoplasms
Interventions
cabozantinib, abiraterone, prednisone
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older · Male only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
20
States / cities
Scottsdale, Arizona • Sedona, Arizona • Tucson, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 22, 2026, 9:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Testing New Models of Diabetes Self-Management to Improve Population Health

NCT06370494
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Living Healthier with Diabetes
Behavioral
Lead sponsor
Texas A&M University
Other
Eligibility
25 Years and older
Enrollment
191 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Oct 22, 2026, 9:02 AM EDT
Completed Phase 2 Interventional Results available

EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma

NCT00114738
View directory record Official record
Conditions
Lymphoma, Mantle Cell, Mantle Cell Lymphoma
Interventions
Rituximab (R), EPOCH, Bortezomib (B), Bortezomib, Bortezomib or observation
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 10, 2022 · Synced Oct 22, 2026, 9:02 AM EDT